Monday's Small-cap Movers under Crystal Research's Coverage

Posted by Laura Swartz

August 6, 2012 at 5:04 PM

CNBC today published an article wherein the founder of Vanguard Group discussed his view on the necessity of investing in equities, which while higher risk, offer the potential for higher reward.

Read More

Topics: Crystal Research Associates, T3 Motion, Advaxis, Bioniche, Pluristem Therapeutics, Peregrine, Adamis

A Solid Start to 2011

Posted by Colleen Koski

January 5, 2011 at 10:11 AM

As we kick off the New Year, many companies within our Coverage Universe are showing a positive start to 2011. For example, Canadian biopharmaceutical company Bioniche Life Sciences Inc. (BNC-TSX) recently raised A$12.5 million in Australia. Biotechnology company Xoma Ltd. (XOMA-NASDAQ) signed a development and licensing agreement potentially valued up to $505 million for an anti-inflammatory drug candidate. In addition, Advanced Cell Technology, Inc. ([“ACT”] ACTC-OTC.BB), a regenerative medicine company, announced that the FDA has cleared its Investigational New Drug application (IND) to test a therapy made from embryonic stem cells in patients with macular degeneration, a leading cause of vision loss. Further, the Tel-Aviv Stock Exchange (TASE) approved the inclusion of Pluristem Therapeutics Inc.’s (PSTI-NASDAQ) ordinary shares on four TASE equity indexes: Tel-Tech, TA Composite, MidCap TA, and Biomed.

Read More

Topics: Newsworthy Events, Bioniche, CEL-SCI, Pluristem Therapeutics

News from Generex, Pluristem, and Vena

Posted by Laura Swartz

October 12, 2010 at 10:50 AM

Read More

Topics: Newsworthy Events, Cameco Corp, Pluristem Therapeutics

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic